Newsroom

Press Releases

April 4, 2023

Business Wire

Qnovia, Inc. Announces Former Director of FDA’s Center for Tobacco Products, Mitch Zeller, as Policy and Regulatory Strategy Advisor

November 8, 2022

Business Wire

Qnovia to Pursue UK Approval for Lead Asset QN-01 in Nicotine Replacement Therapy

September 28, 2022

Business Wire

Qnovia, Inc. Raises $17 Million in Series A Funding to Advance Its Inhalable Therapeutics Pipeline

September 13, 2022

Business Wire

Respira Technologies, Inc. Rebrands as “QNOVIA”; Adopts Qnovia, Inc. as Corporate Name

Media

April 4, 2023

Politico

Former FDA tobacco head: Smokers need a new tool to quit

March 31, 2023

Bloomberg

Ex-FDA Tobacco Head Advising Company on Smoker Cessation

February 24, 2023

Tobacco Reporter

Qnovia Raises $17 million for Nebulizer

January 8, 2023

Barron's

It’s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.

December 27, 2022

PharmaShots

Brian Quigley, CEO at Qnovia Shares his Views on Raising Series A Funding

December 19, 2022

Fierce Pharma

2023 forecast: The biopharma name changing craze and the shifting sands of corporate branding

December 16, 2022

Richmond Biz Journals

Qnovia aims to bring smoking cessation medical device to market in 2025

December 16, 2022

MediaPost

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

December 16, 2022

Flipboard

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

April 4, 2023

Former FDA tobacco head: Smokers need a new tool to quit

April 4, 2023

Qnovia, Inc. Announces Former Director of FDA’s Center for Tobacco Products, Mitch Zeller, as Policy and Regulatory Strategy Advisor

March 31, 2023

Ex-FDA Tobacco Head Advising Company on Smoker Cessation

February 24, 2023

Qnovia Raises $17 million for Nebulizer

January 8, 2023

It’s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.

December 27, 2022

Brian Quigley, CEO at Qnovia Shares his Views on Raising Series A Funding

December 19, 2022

2023 forecast: The biopharma name changing craze and the shifting sands of corporate branding

December 16, 2022

Qnovia aims to bring smoking cessation medical device to market in 2025

December 16, 2022

Have a Project in Mind? Say Hi!

Newsroom

Press Releases

Qnovia, Inc. Announces Former Director of FDA’s Center for Tobacco Products, Mitch Zeller, as Policy and Regulatory Strategy Advisor

Qnovia to Pursue UK Approval for Lead Asset QN-01 in Nicotine Replacement Therapy

Qnovia, Inc. Raises $17 Million in Series A Funding to Advance Its Inhalable Therapeutics Pipeline

Respira Technologies, Inc. Rebrands as “QNOVIA”; Adopts Qnovia, Inc. as Corporate Name

Media

Former FDA tobacco head: Smokers need a new tool to quit

Ex-FDA Tobacco Head Advising Company on Smoker Cessation

Qnovia Raises $17 million for Nebulizer

It’s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.

Brian Quigley, CEO at Qnovia Shares his Views on Raising Series A Funding

2023 forecast: The biopharma name changing craze and the shifting sands of corporate branding

Qnovia aims to bring smoking cessation medical device to market in 2025

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

Former FDA tobacco head: Smokers need a new tool to quit

Qnovia, Inc. Announces Former Director of FDA’s Center for Tobacco Products, Mitch Zeller, as Policy and Regulatory Strategy Advisor

Ex-FDA Tobacco Head Advising Company on Smoker Cessation

Qnovia Raises $17 million for Nebulizer

It’s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.

Brian Quigley, CEO at Qnovia Shares his Views on Raising Series A Funding

2023 forecast: The biopharma name changing craze and the shifting sands of corporate branding

Qnovia aims to bring smoking cessation medical device to market in 2025

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

Address:

Contact us

Investor Relations:

Media Relations:

Links